Unlock instant, AI-driven research and patent intelligence for your innovation.

Bispecific antibody and antibody conjugate for tumour therapy and use thereof

a tumour and antibody technology, applied in the field of specific antibodies, can solve the problems of increased half-life, reduced toxicity, and reduced manufacturing efficiency

Active Publication Date: 2019-09-12
BENHEALTH BIOPHARMACEUTIC SHENZHEN CO LTD
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention provides an antibody fragment that recognizes the MUC1 and CD16 molecules, which are associated with tumor growth. This antibody fragment can be expressed in soluble form in a prokaryotic system and has good thermal stability and high solubility. The invention is also a bispecific antibody that promotes the killing effect of NK cells on MUC1-expressing cells and inhibits the growth of MUC1 positive tumor. The nanobody sequence used in the invention has high homology with the human immunoglobulin sequence and has low antigenicity. Overall, this invention provides a valuable tool for research and potential treatment of MUC1 and CD16-related tumors.

Problems solved by technology

Despite these advances, the main challenges of bispecific antibodies remain, such as increased manufacturing efficiency, retention of immunogenicity, reduced toxicity, and increased half-life.
The latter is widely distributed, abnormally abundantly expressed on the surface of cancer cells, and has incomplete glycosylation, and thus exposes hidden epitope and becomes a target being attacked by immune cells.
In addition, bispecific antibodies may have poor pharmacokinetic and physical properties (such as immunogenicity) as well as manufacturing difficulties.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Bispecific antibody and antibody conjugate for tumour therapy and use thereof
  • Bispecific antibody and antibody conjugate for tumour therapy and use thereof
  • Bispecific antibody and antibody conjugate for tumour therapy and use thereof

Examples

Experimental program
Comparison scheme
Effect test

example 2

ansformation of BL21 (DE3)

[0111]The plasmid was transformed into Escherichia coli DH5a competent cell line, positive clones were selected, cultured in LB medium (3 mL) containing 100 μg / ml ampicillin at 37° C. overnight, the culture solution was centrifuged at 5000 rpm and the supernatant was discarded. The plasmids were extracted from E. coli by using plasmid extraction kit from Qiagen and the expression vector was obtained.

example 3

n and Purification of Anti-MUC1-Anti-CD16

[0112]The purified pETDuet-bsAb expression vector was transformed into E. coli BL21 (DE3) strain, and positive clones were selected and cultured in LB medium (3 mL) containing 100 μg / mL ampicillin overnight at 37° C., and then transferred to 300 mL LB containing 100 μg / mL ampicillin, and the cells were cultured at 37° C. until the OD600 was at 0.6-0.8. IPTG was added at a final concentration of 0.05 mM, and the culture was induced at 16° C. for 16 hours. The culture was centrifuged at 4000 rpm, and the supernatant was discarded. The precipitate was added to a solution of 20 mM Tris-HCl, pH 8.0, 25% sucrose, 1 mM EDTA in a weight-to-volume ratio of 1:4, resuspended, ice-bathed for 30 min, and centrifuged at 4° C., 8500 g, for 20 minutes. The supernatant was taken. The precipitate was added at a weight ratio of 1:5 to solution containing 5 mM MgCl2 and 1 mg / mL lysozyme, ice-cooled for 20 min, and centrifuged at 4° C., 8500 g, for 20 minutes. Th...

example 4

c Antibody In Vitro Binding to MUC1 Test M

Method:

1). Flow Cytometry Detects the Binding of Bispecific Antibody to MUC1

[0119]1. MUC1 positive cells LS174T, HT29, SKOV3 and negative cells CHO, HepG2 cells were cultured in vitro; 0.25% trypsin was digested into single cells, and after centrifugation at 1000 rpm for 10 min, the cell pellet was collected and resuspended in ice-cold PBS+0.2% BSA.

[0120]2. Centrifuged at 4° C., 1000 rpm, for 5 minutes, discarded the supernatant

[0121]3. Resuspend in ice-cold PBS+0.2% BSA and configured to a cell suspension with a concentration of 2*106 / mL.

[0122]4. The primary antibodies (mouse anti-MUC1 / CD66e mAb (1:200); bsAb (10 ug / mL)) were added separately as per the following table and then were incubated for 1 hour at 4° C.

Tube numberPrimary antibodiesSecondary antibodiesANoneGoat-Anti-mouse IgG-FITC (1:500)BAnti-MUC1 (1:200)Goat-Anti-mouse IgG-FITC (1:500)CNoneAnti-His-FITC (1:500)DbsAb (10 ug / mL)Anti-His-FITC (1:500)

[0123]5. Added 5 mL ice-cold PBS+0...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Login to View More

Abstract

Provided in the present invention is a bispecific antibody which comprises an antibody fragment of anti-MUC1 VHH and an antibody fragment of anti-CD16 VHH. The antibody fragment used in the present invention is a variable region sequence derived from a heavy chain camelid antibody and has a high binding affinity to the antigen. Antibody fragments recognizing MUC1 and CD16 are constructed in the same antibody molecule by the invention, so that the antibody molecule can specifically bind to MUC1 and CD16 molecules to promote the killing effect of NK cells on MUC1-positive expression cells and has an inhibiting effect on the growth of MUC1-positive tumors. Also provided is a conjugate of the bispecific antibodies, a related pharmaceutical composition and use.

Description

TECHNICAL FIELD[0001]The present invention relates to a bispecific antibody and the preparation thereof, and more particularly to a bispecific antibody directing to MUC1 and CD16 for use in the field of tumor therapy.BACKGROUND[0002]In tumor immunotherapy, a bispecific antibody (bsAb) plays a very important role. A bispecific antibody is an artificial antibody containing two specific antigen binding sites. The antibody can simultaneously bind to the specific antigens on the surfaces of an effector cell and a target cell through binding sites, activate quiescent effector cells and recruit them around the target cells and mediate apoptosis or lysis of targeting cells. A variety of bsAbs targeting different immune effector cells and tumor cells have been developed, wherein the main immune effector cells in tumor immunotherapy are T cells, NK cells, macrophages and the like. NK cells and T cells are currently the most studied effector cells.[0003]There are molecules having priming effec...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K16/30C07K16/46A61P35/00C07K16/28C12N15/85A61K47/59A61K47/68A61K47/69A61K47/65A61K35/17
CPCA61K47/6937C07K16/3092A61K47/6883C07K16/283A61P35/00A61K47/65C12N15/85C07K16/46A61K35/17A61K47/593C07K17/08C07K2317/31C07K2317/569C07K2317/73C07K16/28A61K39/395
Inventor YU, HAOYANGWANG, ZHONGLI, ZHENGCHENG
Owner BENHEALTH BIOPHARMACEUTIC SHENZHEN CO LTD